SCHEMBL5543729

SCHEMBL5543729

[CH2]CCCc1nc2ccccc2o1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.72
NPC1 O15118 3/20 0.72
RAB9A P51151 3/20 0.72
LOXL2 Q9Y4K0 1/20 0.64
SMN1; SMN2 Q16637 3/20 0.56
TP53 P04637 2/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.55
GFER P55789 1/20 0.55
DRD3 P35462 7/20 0.52
DRD2 P14416 5/20 0.52
DRD4 P21917 3/20 0.52
DRD1 P21728 2/20 0.48
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HTR1A P08908 1/20 0.43
HTR2A P28223 1/20 0.43
KDM4E B2RXH2 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537492 0.95 MAPT (0.76) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL5547331 0.93 MAPT (0.73) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL5538025 0.89 MAPT (0.78) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL11399187 0.89 MAPT (0.84) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL9642061 0.89 MAPT (0.84) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL155002 0.85 MAPT (1.00) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL2986628 0.82 NPC1 (0.72) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL4280291 0.82 MAPT (0.72) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL591905 0.82 RAB9A (0.72) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL22871601 0.82 MAPT (0.72) MAPTNPC1RAB9ALOXL2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885NPC1 2404/4885RAB9A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.